

[Open Peer Review on Qeios](#)

Briakinumab

National Cancer Institute

Source

National Cancer Institute. *Briakinumab*. NCI Thesaurus. Code C95321.

A human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. Briakinumab binds to both IL-12 and IL-23, which prevents IL-12- and IL-23-mediated signaling. This may suppress immune responses mediated by these interleukins. The cytokines IL-12 and IL-23 play an important role during inflammation.